This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation. Not available for sale.
Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
Herein, we provide an overview of the current knowledge on the pathophysiology and risk factors for AF in adult congenital heart disease, with a special focus on the existing challenges in AF ablation. Emerging imaging modalities and ablation techniques might have a role to play.
Circulation, Ahead of Print. BACKGROUND:Current outcomes from catheter ablation for scar-dependent ventricular tachycardia (VT) are limited by high recurrence rates and long procedure durations. Predicted optimum ablation sites to terminate all VTs in the models were identified.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). iii] The study reported a low fluoroscopy time of 7.8
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. CONCLUSIONS:The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. versus 72%;P=0.41).
Circulation, Volume 150, Issue Suppl_1 , Page A4142266-A4142266, November 12, 2024. Recurrence rates after catheter ablation in these patients are high. Ablation success rate was 92%. Recurrence occurred in 12 (48%) patients, with 7 (28%) requiring repeat ablations repeat within 5 years.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:It is difficult to identify patients with atrial fibrillation (AF) most likely to respond to ablation. We compared 6 machine learning models to predict acute and long-term end points after ablation and used Shapley explainability analysis to contrast phenotypes.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. We investigate whether additional linear ablation from the superior vena cava to the right atrial septum and cavotricuspid isthmus ablation improves the rhythm outcome of patients with persistent AF undergoing cryoballoon PVI (Cryo-PVI).METHODS:In
Circulation, Volume 150, Issue Suppl_1 , Page A4141954-A4141954, November 12, 2024. Flow simulation results showed that ablation of index valve leaflets can effectively mitigate the flow obstruction caused by sinus sequestration in redo-TAVR, with the extent of restoration dependent on the number and location of the ablated openings (Fig.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Background:Pulsed field ablation (PFA) has emerged as an alternative to radiofrequency ablation. However, data on focal point-by-point PFA are scarce.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Power-controlled radiofrequency ablation with irrigated-tip catheters has been the norm for ventricular ablation for almost 2 decades. Four and one of these sets of parameters were further tested in phases II and III, respectively. mm), withP<0.05
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Epicardial approach in ventricular tachycardia (VT) ablation is still regarded as a second-step strategy, due to the risk of complications. The epicardial approach was considered useful if epicardial ablation was performed after epicardial mapping.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Inflammation may promote atrial fibrillation (AF) recurrence after catheter ablation. The first dose of the study drug was administered within 4 hours before ablation. 1.61];P=0.92) or at 3 months following ablation (14% versus 15%; HR, 0.95 [95% CI, 0.45–2.02];P=0.89).
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation uses electrical fields to cause nonthermal cell death over several hours. Acute changes in tissue birefringence and voltage abatement were analyzed for each individual lesion.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Sequential application of radiofrequency with pulsed field (PF) ablation may increase lesion depth while preserving the advantages of PF. Ablations were performed with a force-sensing 3.5-mm Radiofrequency was delivered at 50 W for 10 s (15 mL/min).
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:The effect of contact force (CF) on lesion formation is not clear during pulsed field ablation (PFA). Further studies are required to evaluate the best PFA ablation settings to achieve transmural lesions.
Circulation, Volume 150, Issue Suppl_1 , Page A4141066-A4141066, November 12, 2024. Background:Clinical studies on atrial fibrillation (AF) recurrence after catheter ablation in patients diagnosed with patent foramen ovale (PFO) and paroxysmal AF (PAF) are scarce.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Epicardial radiofrequency catheter ablation (RFCA) of idiopathic ventricular arrhythmias (VAs) originating from the left ventricular summit (LVS) is challenging because of the anatomic barriers.
Circulation, Volume 150, Issue Suppl_1 , Page A4141988-A4141988, November 12, 2024. Background:Catheter ablation (CA) is an effective treatment for atrial fibrillation (AF), but many patients experience recurrence post-intervention. The addition of LAVI values provided better discrimination for the ROC model.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Background:Effects of contact force (CF) on lesion formation during pulsed field ablation (PFA) have not been well validated. mm ablation electrode and CF sensor (TactiCath SE, Abbott) was connected to a PFA system (CENTAURI, Galvanize Therapeutics).
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%87.4%)
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Electroporation is a promising nonthermal ablation method for cardiac arrhythmia treatment.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging.
Circulation, Ahead of Print. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
In contrast to other tachycardias, with atrial fibrillation (AF), the focus is often speculative, and ablation attempts are made accordingly. Pulmonary veins have been the primary target for ablation for many years, yet the success rates remain inconsistent. Implications for electrophysiologists.
Circulation, Ahead of Print. BACKGROUND:During the neonatal stage, the cardiomyocyte undergoes a constellation of molecular, cytoarchitectural, and functional changes known collectively as cardiomyocyte maturation to increase myocardial contractility and cardiac output.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
115 
Let's personalize your content